<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100124003146N10</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-19</date_registration>
      <primary_sponsor>Kashan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of two methods of bowel feeding and continuous in intensive care patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of two methods of bolus and continuous enteral feeding on biochemical and clinical indicators of trauma patients admitted to intensive care units</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>74</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63673</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, the block randomization method was used in blocks 4 and 6, which were prepared using the online randomization software (www.sealedenvelope.com). In this software, two groups A (continuous feeding group) and B (bolus feeding group) were defined. Then, according to the total number of samples, which was 74, to increase the validity of randomization, two blocks of 6 and 4 blocks were defined with the approval of a statistician.Then, the researcher will be present in the section and will put the samples with the word criteria into groups based on the list obtained from the randomization software, Blinding description: In this study, nurses will only be aware of the type of gavage for the patient, but will not know which patient is in the experimental group and which patient is in the control group. Also, the person who collects the study data and the person who will analyze them will not know the names of the groups and only the names of the groups will be marked with the letters A and B.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Nutritional support in intensive care. Condition 2: Nutritional support in intensive care.</hc_freetext>
      <i_freetext>Intervention 1: The enteral nutrition group will be the intervention group in a continuous manner. In the intervention group, enteral feeding will be done continuously (for 24 hours and in the form of an infusion of 20 drops per minute, which will be 2000 cc for a total of 24 hours). The food item (Karen's Standard Intermeal powder) will be prepared and given by the nutrition expert in a standard way for both groups in the same volume every 24 hours. The duration of intervention in both groups will last seven days. Intervention 2: The control group will be given enteral feeding in the form of bolus using a gavage syringe and under gravity every 3 hours, 250 cc of food will be given in 10 to 20 minutes, for a total of 24 hours of 2000 cc of standard Intrameal solution dissolved by a nutritionist. , will be given. The food item (Karen's Standard Intermeal powder) which will be prepared and given by the nutrition expert in a standard way for both groups in the same volume every 24 hours. The duration of intervention in both groups will last seven days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
the results related to the main outcome will be distributed

When:
after the publication of the article

To whom:
All people

Conditions:
data will be confidential

Where to obtain:
azizifinies@yahoo.com

How to obtain:
En the process will be announced later

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ismail Azizi-Fini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>5Th Kilometer Qotb Ravandi blouvar.kashan university of medical sciences</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8715981151</zip>
        <telephone>+98 31 5554 0021</telephone>
        <email>azizifinies@yahoo.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ismail Azizi-Fini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>5th kilometer Qotb Ravandi Blouvar</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8715981151</zip>
        <telephone>+98 31 5554 0021</telephone>
        <email>azizifinies@yahoo.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Being hospitalized in the intensive care unit
Intestinal feeding through the nasogastric tube is prescribed by a doctor
Have stable and normal hemodynamic conditions.
The patient has a head trauma.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Age over 60 years
The patient has intravenous nutrition
The patient has a kidney or liver disorder</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E43</hc_code>
      <hc_code>J98.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unspecified severe protein-calorie malnutrition</hc_keyword>
      <hc_keyword>Other disorders of lung</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The enteral nutrition group will be the intervention group in a continuous manner. In the intervention group, enteral feeding will be done continuously (for 24 hours and in the form of an infusion of 20 drops per minute, which will be 2000 cc for a total of 24 hours). The food item (Karen's Standard Intermeal powder) will be prepared and given by the nutrition expert in a standard way for both groups in the same volume every 24 hours. The duration of intervention in both groups will last seven days.</i_keyword>
      <i_keyword>The control group will be given enteral feeding in the form of bolus using a gavage syringe and under gravity every 3 hours, 250 cc of food will be given in 10 to 20 minutes, for a total of 24 hours of 2000 cc of standard Intrameal solution dissolved by a nutritionist. , will be given. The food item (Karen's Standard Intermeal powder) which will be prepared and given by the nutrition expert in a standard way for both groups in the same volume every 24 hours. The duration of intervention in both groups will last seven days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Remaining volume in the stomach. Timepoint: Daily. Method of measurement: Gavage syringe(50 cc).</prim_outcome>
      <prim_outcome>Level of Albumin. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood biochemistry test device.</prim_outcome>
      <prim_outcome>Number of intestinal excretions. Timepoint: daily. Method of measurement: checklist.</prim_outcome>
      <prim_outcome>Occurrence of pulmonary aspiration. Timepoint: daily. Method of measurement: checklist.</prim_outcome>
      <prim_outcome>Number of vomiting. Timepoint: daily. Method of measurement: checklist.</prim_outcome>
      <prim_outcome>Stomach bleeding. Timepoint: daily. Method of measurement: checklist.</prim_outcome>
      <prim_outcome>Total blood protein level. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood biochemistry test device.</prim_outcome>
      <prim_outcome>White blood cell level. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood analyzer.</prim_outcome>
      <prim_outcome>Whole blood lymphocyte count. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood analyzer.</prim_outcome>
      <prim_outcome>Blood hemoglobin level. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood analyzer.</prim_outcome>
      <prim_outcome>Hematocrit level. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood analyzer.</prim_outcome>
      <prim_outcome>Blood urea level. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood biochemistry test device.</prim_outcome>
      <prim_outcome>Blood creatinine level. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood biochemistry device.</prim_outcome>
      <prim_outcome>Blood calcium level. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood biochemistry device.</prim_outcome>
      <prim_outcome>Blood phosphorus level. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood biochemistry device.</prim_outcome>
      <prim_outcome>Blood phosphorus level. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood biochemistry device.</prim_outcome>
      <prim_outcome>Blood cholesterol level. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood biochemistry device.</prim_outcome>
      <prim_outcome>Blood triglyceride levels. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood biochemistry device.</prim_outcome>
      <prim_outcome>Blood aspartate aminotransferase level. Timepoint: Before intervention, 3 and 7 days after intervention. Method of measurement: Blood biochemistry device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Weaning from the ventilator. Timepoint: End of intervention. Method of measurement: Checklist.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kashan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-16</approval_date>
        <contact_name>Ethics Committee of the Faculty of Nursing and Midwifery, Health and Paramedicine - Kashan Universit</contact_name>
        <contact_address>5th kilometer Qotb Ravandi blouvar kashan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
